Approval · Notice of Compliance 8811 · 2007
LAMISIL: Notice of Compliance 8811
Issued June 4, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 8811
- Date
- June 4, 2007
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Changes to the product monograph to reflect safety-related updates
- Therapeutic class
- Antifungal agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LAMISIL | Not yet assigned | — |
Medicinal ingredients
- TERBINAFINE HCL 250 MG per TAB
- TERBINAFINE HCL 10 MG per G
- TERBINAFINE HCL 125 MG per TAB